Harbor Advisory Corp MA cut its holdings in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 4.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,816 shares of the financial services provider’s stock after selling 588 shares during the period. Harbor Advisory Corp MA’s holdings in iShares Biotechnology ETF were worth $1,562,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Comprehensive Financial Planning Inc. PA bought a new position in iShares Biotechnology ETF in the 4th quarter worth $47,000. Angeles Wealth Management LLC grew its holdings in iShares Biotechnology ETF by 2,083.3% during the fourth quarter. Angeles Wealth Management LLC now owns 524 shares of the financial services provider’s stock valued at $69,000 after purchasing an additional 500 shares during the period. Martin Capital Advisors LLP increased its position in iShares Biotechnology ETF by 9.6% in the fourth quarter. Martin Capital Advisors LLP now owns 14,439 shares of the financial services provider’s stock worth $1,909,000 after buying an additional 1,270 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new position in shares of iShares Biotechnology ETF in the fourth quarter worth about $33,000. Finally, Kestra Private Wealth Services LLC lifted its position in shares of iShares Biotechnology ETF by 25.3% during the 4th quarter. Kestra Private Wealth Services LLC now owns 6,365 shares of the financial services provider’s stock valued at $842,000 after buying an additional 1,284 shares in the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.
iShares Biotechnology ETF Trading Down 1.4 %
Shares of NASDAQ:IBB opened at $134.24 on Wednesday. The stock has a 50 day moving average of $135.99 and a 200 day moving average of $141.17. iShares Biotechnology ETF has a 12-month low of $123.60 and a 12-month high of $150.57.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
See Also
- Five stocks we like better than iShares Biotechnology ETF
- What is the Hang Seng index?
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- Manufacturing Stocks Investing
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- How to Evaluate a Stock Before Buying
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.